Enter multiple symbols separated by commas



  • BUZZ-SALIX PHARMACEUTICALS PLC: VALEANT RAISES ALL-CASH OFFER@** American drugmaker's shares up 2 pct at $173. **Canadian drugmaker Valeant Pharmaceuticals International Inc raised its offer to buy Salix to $173 from $158 in cash. **Sources told Reuters on Friday Valeant was working with its top shareholders on plans to raise its offer for Salix, sending Dublin-...

  • After France, Ireland wants EU budget flexibility too Tuesday, 10 Mar 2015 | 12:39 PM ET

    *Ireland wants to have more spending space in 2016 budget. BRUSSELS, March 10- Ireland demanded more leeway on Tuesday for its budget spending next year after the European Commission showed leniency in applying EU rules to France and Italy. European Union finance ministers on Tuesday endorsed a Commission recommendation to give France, which has repeatedly...

  • DUBLIN, March 8- Fresh from putting the squeeze on banks to behave themselves, regulators are now scrutinising so-called shadow banks, alternative lenders like investment funds that are doing big business out of countries such as Ireland. The third biggest shadow banking market in the euro zone behind Luxembourg and the Netherlands, Ireland has amassed 2.9...

  • Ireland's return to the bond markets: Reaction   Thursday, 5 Mar 2015 | 7:40 AM ET
    Ireland return to the bond markets: Reaction

    Rossa White, chief economist at NTMA, talks about Ireland's turnaround in the bond markets.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • Is the Irish recovery stable?   Wednesday, 4 Mar 2015 | 11:10 AM ET
    Is the Irish recovery stable?

    Deirdre Somers, CEO of the Irish Stock Exchange, talks about the Irish economy and the Irish stock exchange's position compared to other European stock exchanges.

  • Greece can learn from us: Irish PM   Wednesday, 4 Mar 2015 | 4:00 AM ET
    Greece can learn from us: Irish PM

    Endy Kenny, Taoiseach of Ireland, talks about his country's relationship with the Troika and gives some advice to Greece.

  • Irish PM: From austerity to recovery   Wednesday, 4 Mar 2015 | 4:00 AM ET
    Irish PM: From austerity to recovery

    Despite a recovery in Ireland, there are still fragile areas of concern. Endy Kenny, Taoiseach of Ireland, discusses these, but says a "recovery is underway" for Ireland.

  • Irish PM: We're 'upfront' about tax   Wednesday, 4 Mar 2015 | 4:00 AM ET
    Irish PM: We're 'upfront' about tax

    Endy Kenny, Taoiseach of Ireland, discusses the country's tax structure and whether this is attractive to big companies.

  • We're targeting foreign investment: Irish CEO   Wednesday, 4 Mar 2015 | 3:30 AM ET
    We're targeting foreign investment: Irish CEO

    Martin Shanahan, CEO of IDA Ireland, says Ireland saw an impressive amount of foreign direct investment in 2014.

  • Why Ireland needs retirement reforms: CEO   Wednesday, 4 Mar 2015 | 2:50 AM ET
    Why Ireland needs retirement reforms: CEO

    Speaking to CNBC, Bill Kyle, CEO of Irish Life Group, said Ireland needs to look at retirement reform.

  • Strong growth ahead for Ireland: CEO   Wednesday, 4 Mar 2015 | 1:20 AM ET
    Strong growth ahead for Ireland: CEO

    Danny McCoy, CEO of IBEC, tells CNBC that despite high debt levels in Ireland, he sees a strong year of growth ahead.

  • Ireland must support SMEs: CEO   Wednesday, 4 Mar 2015 | 1:20 AM ET
    Ireland must support SMEs: CEO

    Gary McGann, CEO of Smurfit Kappa, tells CNBC that Ireland needs to support SMEs which are fundamental to a sustainable recovery.

  • FACTBOX-How Europe's "bad banks" have fared Monday, 2 Mar 2015 | 12:12 PM ET

    Belgium had two major banking failures, Fortis and Dexia. With the former, toxic assets were purchased for 11.7 billion euros by a separate vehicle Royal Park Investments, owned by Fortis, the Belgian state and BNP Paribas. Credit Suisse and Lone Star Funds bought RPI's assets for 6.7 billion euros in 2013. RPI is active now only in U.S. legal disputes.

  • DUBLIN/ MADRID, March 2- Europe's tough treatment of Greece's new government has eased some immediate anti-austerity pressure in Ireland and Spain, but it may take a lot more than that to put Dublin and Madrid's ruling parties' re-election prospects back on track. They both toed the line with Germany in demanding that Greece stick to its bailout commitments- a...

  • Dublin- based Actavis Plc holds the commercial license for the product, but the marketing application was submitted by non-profit pharmaceutical company Medicines360, which holds the U.S. public sector clinic rights. The companies expect the device, which also helps to check heavy menstrual bleeding, to be available in the United States by the second quarter...

  • DUBLIN, Feb 26- Malin, an Irish company set up by a number of former Elan executives to invest in privately held life science assets, said it plans to raise between 275 million and 325 million euros in one of Europe's biggest biotechnology IPOs. Former Elan chief executive Kelly Martin and chairman Bob Ingram, who sold the Irish stock market stalwart to Perrigo for...

  • Cramer Remix: This stock, and llamas, on the run Thursday, 26 Feb 2015 | 7:06 PM ET

    Llamas weren’t the only things running wild on Thursday; “Mad Money” host Jim Cramer has a stock galloping higher.

  • Cramer: 'I'm a happy camper'—Thanks, Europe! Thursday, 26 Feb 2015 | 6:22 PM ET
    Mario Draghi, president of the European Central Bank (ECB), looks on as he unveils a new twenty-euro banknote at the ECB headquarters in Frankfurt, Germany, Feb. 24, 2015.

    Jim Cramer wants to be negative about what's happening in the market right now but with this evidence, he can't!